On January 16, Mark R. BAMFORTH, Senior Vice President and CEO of Genzyme led a delegation on a visit to the China National Center for BioTechnology Development. Deputy Director-General JIA Feng of the Center received the delegation.

Genzyme has branches in over 30 countries worldwide. The company invests about 500-600 million dollars for drug research and development each year. 26 drugs have been approved to tackle Lysosomal Storage Disorders in over 80 countries. In recent years, Genzyme has been offering free treatment to children infected by Gaucher disease in China and other countries in the world.